abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

IL2RA
Back
Total number of drugs
67
Phase II and later clinical stages
16.4%
Involving companies
76
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
WO2023245021WO2023245021Bispecific antibodyNeoplasmsInvenra, Inc.Invenra, Inc.DiscoveryWO2023245021
detail  >
INO-9112INO-9112DNA vaccine Prophylactic vaccineInfectious Diseases Digestive System Disorders Respiratory DiseasesInterleukin-2 receptor alpha chain agonistsInovio Pharmaceuticals, Inc.Phase 1INO-9112
detail  >
AST-202AST-202Therapeutic vaccine mRNA vaccineNeoplasms Endocrinology and Metabolic Disease Urogenital DiseasesInterleukin-2 receptor alpha chain inhibitorsAston SCIPreclinicalAST-202
detail  >
Anti-interleukin-2 receptor monoclonal antibody 33B3-1(Immunotech)Anti-interleukin-2 receptor monoclonal antibody 33B3-1(Immunotech)Monoclonal antibodyImmune System DiseasesInterleukin-2 receptor alpha chain inhibitorsImmunotechDiscontinuedAnti-interleukin-2 receptor monoclonal antibody 33B3-1(Immunotech)
detail  >
Albumin-interleukin-2Albumin-interleukin-2InterleukinsNeoplasmsInterleukin-2 receptor alpha chain agonistsCSL Behring LLCDiscontinuedAlbumin-interleukin-2
detail  >
WO2024213046WO2024213046AntibodyNeoplasms Immune System DiseasesSuzhou Transcenta Therapeutics Co., Ltd.Suzhou Transcenta Therapeutics Co., Ltd.DiscoveryWO2024213046
detail  >
WO2024131023WO2024131023NanobodyNeoplasmsDiscoveryWO2024131023
detail  >
WO2024034759WO2024034759Radiolabeled antibodyNeoplasms Immune System Diseases Hemic and Lymphatic DiseasesSamsung Life Public Welfare FoundationResearch & Business Foundation Sungkyunkwan UniversitySamsung Life Public Welfare FoundationResearch & Business Foundation Sungkyunkwan UniversityDiscoveryWO2024034759
detail  >
WO2024006961WO2024006961Recombinant polypeptideImmune System Diseases Nervous System Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal DiseasesNeurogene, Inc.Neoleukin Therapeutics, Inc.Neurogene, Inc.DiscoveryWO2024006961
detail  >
TGI-18TGI-18Trispecific antibodyNeoplasmsInterleukin-2 receptor alpha chain inhibitors Programmed cell death protein 1 inhibitors Vascular endothelial growth factor inhibitorsHefei TG ImmunoPharma Co., LtdHefei TG ImmunoPharma Co., LtdPreclinicalPreclinicalTGI-18
detail  >
Total 67 data
1
2
3
4
5
6
7